[144] EPR Properties SEC Filing

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Ltd. (TEVA) – Form 144 notice

An unidentified affiliate has filed to sell up to 6,053 ordinary shares via Citigroup Global Markets on the NYSE, with an aggregate market value of roughly US$91,748. The shares were acquired as a restricted-share-unit award on 01 Aug 2022 and satisfy Rule 144’s two-year holding-period requirement. The proposed trade window opens on 01 Aug 2025.

Teva has about 1.147 billion shares outstanding, so the sale would equal <0.001 % of the float—far below any level that could affect liquidity, ownership concentration or voting control. A Form 144 is only a notice; the transaction may not ultimately occur and no pricing details were provided beyond the broker of record.

Positive

• None.

Negative

• Insider selling signal: Even though the volume is trivial, any planned insider sale can be perceived negatively by some investors tracking management sentiment.

Insights

Securities Analyst

TL;DR: De minimis insider sale; neutral for valuation.

The 6,053-share sale equates to under US$0.1 m against Teva’s multi-billion-dollar market cap and >1 billion share count. Such a small disposition will not affect liquidity or EPS and does not imply strategic change. Insider intent might garner minor attention, but the transaction volume is immaterial. Overall, I view the filing as routine administrative disclosure with no discernible impact on the investment thesis.

Corporate Governance Expert

TL;DR: Routine Rule 144 compliance; governance risk unchanged.

The filer certifies no undisclosed adverse information, satisfying Rule 144 and 10b5-1 safeguards. Absence of recent clustered insider selling or large volume keeps governance risk unchanged. I classify the event as not impactful to shareholders’ governance considerations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th Floor New York NY 10010	7500	411750.00	76116634	08/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/21/2025	Compensation	Issuer			7500	02/21/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Gregory Zimmerman 909 Walnut Street Suite 200 Kansas City MO 64106	Common	07/01/2025	7500	437784.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the TEVA Form 144 disclose?

It disclosed an insider's intent to sell 6,053 ordinary shares valued at about US$91,748.

When can the TEVA shares be sold under Rule 144?

The filing lists an approximate sale date of 01 Aug 2025.

How significant is the planned sale relative to TEVA’s float?

With 1.147 billion shares outstanding, the sale equals <0.001 % of total shares.

Where will the sale take place and who is the broker?

The shares are slated for sale on the NYSE through Citigroup Global Markets.

Were the shares purchased or awarded?

They were acquired as a restricted share-unit award on 01 Aug 2022.

Does the filing guarantee the transaction will occur?

No. Form 144 is only a notice; the insider may decide not to execute the sale.